Chengdu University of Traditional Chinese Medicines   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chengdu China (1956)

Organization Overview

First Clinical Trial
2002
NCT01475578
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Affiliated Hospital of Chengdu University of Traditional Chinese Medicines | Chengdu University of TCM | Chengdu University of Traditional Chinese Medicine | Chengdu Women and Children's Hospital | Ineye Hospital of Chendu University of TCM | School of Acupunture& Tuina, Chengdu University of Traditional Chinese Medicine | Teaching Hospital of Chengdu University of TCM | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine | the chief of the neurology department, the Affiliated Hospital of Chengdu Chinese Traditional Medicine

Active Ingredients

Drugs in Phase 4 Trials (5)

deng zhan sheng mai (1 trial)

levofloxacin (levaquin) (1 trial)

qianjin (1 trial)

shenyankangfu (1 trial)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (7)

cyproviron (1 trial)

diclofenac (voltaren) (2 trials)

estradiol (progynon depot) (1 trial)

ibuprofen (motrin) (2 trials)

loperamide (imodium) (1 trial)

megestrol (megace) (1 trial)

tong-xie-yao-fang (1 trial)

Drugs in Phase 2 Trials (17)

benazepril (lotensin) (1 trial)

buqitongluo (1 trial)

caffeine (1 trial)

danshen (1 trial)

dipyridamole (persantine) (1 trial)

enoxaparin (lovenox) (1 trial)

ergoloid mesylate (1 trial)

fluoxetine (prozac) (1 trial)

hydroquinone (1 trial)

neostigmine (bloxiverz) (1 trial)

prednisone (meticorten) (1 trial)

qideng mingmu (1 trial)

sailuotong (1 trial)

sta-1 (1 trial)

tang ning tongluo (1 trial)

tripterygium wilfordii (1 trial)

yi-zhi-an-shen (1 trial)

Drugs in Phase 1 Trials (13)

acetylsalicylic acid (aspirin) (1 trial)

allium macrostemon bunge (1 trial)

atorvastatin (lipitor) (1 trial)

borneol (1 trial)

frankincense (1 trial)

kirilowii maxim (1 trial)

leeches (1 trial)

metoprolol (lopressor) (1 trial)

mudan (1 trial)

ramipril (altace) (1 trial)

santalum (1 trial)

styrax (1 trial)

trichosanthes (1 trial)

Drugs in Other Trials (9)

dezocine (dalgan) (1 trial)

eszopiclone (lunesta) (1 trial)

itropride (1 trial)

jinlianqingre (1 trial)

metoclopramide (reglan) (1 trial)

qi ming (1 trial)

sufentanil (1 trial)

sulodexide (Aterina) (1 trial)

thiamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 2)

Angina, Stable (Phase 2)

Anorexia (Phase 3)

Back Pain (Phase 3)

Blind Loop Syndrome (Phase 2)

Cachexia (Phase 3)

Cerebral Infarction (Phase 4)

Cognitive Dysfunction (Phase 2)

Communicable Diseases (Phase 4)

Coronary Artery Disease (Phase 2)

Dementia (Phase 2)

Dementia, Vascular (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Diabetic Retinopathy (Phase 2)

Diarrhea (Phase 3)

Disease (Phase 2)

Dysmenorrhea (Phase 1)

IgA Vasculitis (Phase 2)

Infections (Phase 4)

Irritable Bowel Syndrome (Phase 3)

Ischemia (Phase 4)

Low Back Pain (Phase 3)

Nephritis (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pelvic Infection (Phase 4)

Pelvic Inflammatory Disease (Phase 4)

Peripheral Nervous System Diseases (Phase 2)

Purpura (Phase 2)

Retinal Diseases (Phase 2)

Stroke (Phase 4)

Syndrome (Phase 3)

Urinary Tract Infections (Phase 4)

Wasting Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 51